HRP20150524T1 - Protutijela za il-25 - Google Patents

Protutijela za il-25 Download PDF

Info

Publication number
HRP20150524T1
HRP20150524T1 HRP20150524TT HRP20150524T HRP20150524T1 HR P20150524 T1 HRP20150524 T1 HR P20150524T1 HR P20150524T T HRP20150524T T HR P20150524TT HR P20150524 T HRP20150524 T HR P20150524T HR P20150524 T1 HRP20150524 T1 HR P20150524T1
Authority
HR
Croatia
Prior art keywords
gly
ser
val
tyr
thr
Prior art date
Application number
HRP20150524TT
Other languages
English (en)
Croatian (hr)
Inventor
David John Matthews
Jillian Barlow
Andrew Neil James Mckenzie
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of HRP20150524T1 publication Critical patent/HRP20150524T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150524TT 2008-09-30 2009-09-30 Protutijela za il-25 HRP20150524T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10129308P 2008-09-30 2008-09-30
GBGB0817891.5A GB0817891D0 (en) 2008-09-30 2008-09-30 Antibodies against il-25
EP09795802.9A EP2344538B1 (en) 2008-09-30 2009-09-30 Antibodies against il-25
PCT/IB2009/007302 WO2010038155A2 (en) 2008-09-30 2009-09-30 Antibodies against il-25

Publications (1)

Publication Number Publication Date
HRP20150524T1 true HRP20150524T1 (hr) 2015-08-14

Family

ID=40019808

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150524TT HRP20150524T1 (hr) 2008-09-30 2009-09-30 Protutijela za il-25

Country Status (22)

Country Link
US (1) US8658169B2 (enExample)
EP (1) EP2344538B1 (enExample)
JP (1) JP5719771B2 (enExample)
KR (1) KR101659452B1 (enExample)
CN (1) CN102245638B (enExample)
AU (1) AU2009299465B2 (enExample)
BR (1) BRPI0919062A2 (enExample)
CA (1) CA2739050C (enExample)
CY (1) CY1116313T1 (enExample)
DK (1) DK2344538T3 (enExample)
ES (1) ES2537226T3 (enExample)
GB (1) GB0817891D0 (enExample)
HR (1) HRP20150524T1 (enExample)
ME (1) ME02219B (enExample)
MX (1) MX2011003351A (enExample)
NZ (1) NZ592274A (enExample)
PL (1) PL2344538T3 (enExample)
PT (1) PT2344538E (enExample)
RS (1) RS54028B1 (enExample)
SI (1) SI2344538T1 (enExample)
SM (1) SMT201500144B (enExample)
WO (1) WO2010038155A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
PL2552961T3 (pl) * 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
JP6284181B2 (ja) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状ｒｎａ及びタンパク質の製造方法
CN103792375B (zh) * 2014-01-29 2017-07-07 华中科技大学同济医学院附属同济医院 外周血白细胞介素25水平在哮喘分型中的应用及分型方法
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
EP3430046A4 (en) * 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
AU2018450414B2 (en) * 2018-11-19 2025-10-16 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-IL-25 antibodies and use thereof
GB202018015D0 (en) * 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
EP4569000A4 (en) * 2022-08-12 2026-07-15 Lycia Therapeutics Inc Bispecific antibodies and constructions for lysosomal targeting degradation and their methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0276846A3 (en) 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
NZ542988A (en) 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
EP1863520B1 (en) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Use of interleukin 17e for the treatment of cancer
WO2007044450A2 (en) * 2005-10-06 2007-04-19 Baylor Research Institute Compositions and methods for the treatment of cancer
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
PL2552961T3 (pl) * 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
PL2344538T3 (pl) 2015-10-30
CY1116313T1 (el) 2017-02-08
CA2739050C (en) 2018-05-29
BRPI0919062A2 (pt) 2015-12-15
KR20110086013A (ko) 2011-07-27
CN102245638A (zh) 2011-11-16
WO2010038155A2 (en) 2010-04-08
CA2739050A1 (en) 2010-04-08
ME02219B (me) 2016-02-20
US20110250195A1 (en) 2011-10-13
AU2009299465B2 (en) 2012-07-26
EP2344538A2 (en) 2011-07-20
AU2009299465A1 (en) 2010-04-08
EP2344538B1 (en) 2015-02-25
SMT201500144B (it) 2015-09-07
RS54028B1 (sr) 2015-10-30
NZ592274A (en) 2012-08-31
MX2011003351A (es) 2011-05-25
WO2010038155A3 (en) 2010-05-27
HK1154022A1 (en) 2012-04-13
PT2344538E (pt) 2015-06-19
DK2344538T3 (en) 2015-06-01
ES2537226T3 (es) 2015-06-03
US8658169B2 (en) 2014-02-25
JP2012503979A (ja) 2012-02-16
SI2344538T1 (sl) 2015-07-31
GB0817891D0 (en) 2008-11-05
KR101659452B1 (ko) 2016-09-23
CN102245638B (zh) 2014-10-22
JP5719771B2 (ja) 2015-05-20

Similar Documents

Publication Publication Date Title
ME02219B (me) Antitela protiv il-25
CN115461368B (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
EP3233922B1 (en) Blood brain barrier transport molecules and uses thereof
TWI449709B (zh) 能結合胸腺基質淋巴細胞生成素之抗體及其製造方法與用途
KR101836217B1 (ko) Ｉｌ-１７ａ 길항제
JP2012503979A5 (enExample)
CN102300997B (zh) Toll样受体3拮抗剂
HRP20180340T1 (hr) Humanizirana il-25 protutijela
EP1972637B1 (en) huTNFR1 selective antagonists
Kolbinger et al. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies
HRP20161548T1 (hr) Protutijela za il-25
KR101739489B1 (ko) 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도
CA2585043A1 (en) High affinity antibodies against hmgb1 and methods of use thereof
EP3170839B1 (en) POLYMERIC IgA-TYPE RECOMBINANT ANTIBODY AND USE THEREOF
AU2005259992A1 (en) Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
KR20150056788A (ko) 면역원성이 감소된 항체의 동정 방법
CA2744065A1 (en) Process for the modulation of the antagonistic activity of a monoclonal antibody
JP2025512865A (ja) 抗血清アルブミンナノボディおよびその誘導体
EP4177267A1 (en) Anti-surrogate light chain antibodies
EP2425008B1 (en) Toll-like receptor 3 antagonists
WO2014052188A1 (en) Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
TW202237651A (zh) 靶向ＣＤ３９及ＴＧＦβ之新穎結合物分子
CN113728006A (zh) 新型抗ifnar1抗体
KR20220064331A (ko) SARS-CoV-2에 대한 단일 도메인 항체 및 이의 용도
EP3980125A1 (en) Bispecific binding constructs